’Antineoplastons’: An Unproved Cancer Therapy

JAMA: The Journal of the American Medical Association

Volumn 267, Issue 21, 1992, Pages 2924-2928

  Green, Saul ^a  

^a Zol Consultants Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYLACETAMIDO 2,6 PIPERIDINEDIONE; PEPTIDE;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER REGRESSION; DISEASE PREDISPOSITION; HUMAN; HYPOTHESIS; PRIORITY JOURNAL; REVIEW; UNITED STATES;

HUMAN; NEOPLASMS; PEPTIDES; PIPERIDINES; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0026503106     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1992.03480210086037     Document Type: Article

References (40)

1. Pepper C. Quackery: A $10 Billion Scandal: A Report by the Chairman of the Subcommittee on Health and Long Term Care. Washington, DC: US Senate; May 31, 1984. Publication 98-435.
2. Rutz D. People With Cancer: Taking Charge or Taking Chances [videotape]. Atlanta, Ga: Cable News Network; April 21, 1990.
3. Burzynski SR, Georgiades J. Effects of urinary peptides on DNA, RNA and protein synthesis in normal and neoplastic cells. Fed Proc. 1973;32:766.
4. Burzynski SR. Antineoplastic Peptides From Urine. National Cancer Institute grant CA 15056; 1974.
5. Burzynski SR, Loo TL, Ho DH, Rao PN, Georgiades J, Kratzenstein H. Biologically active peptides in human urine. Physiol Chem Phys. 1976;8: 13-22.
6. Burzynski SR. Antineoplastons: a biochemical defense against cancer. Physiol Chem Phys. 1976; 8:276-279.
7. Burzynski SR, Stolzmann Z, Szopa B, Stolzmann E, Kaltenberg OP. Antineoplaston A in cancer therapy. Physiol Chem Phys. 1977;9:485-500.
8. Burzynski SR. Purified Antineoplaston Fractions and Methods of Treating Neoplastic Disease. US patent 4558057; December 10, 1985.
9. The Burzynski Clinic. Houston, Tex: Burzynski Research Institute; 1990. Promotional brochure.
10. Ungar G, Burzynski SR. Detection of a behavior inducing peptide from brains of trained rats. Fed Proc. 1972;31:398.
11. Ungar G, Burzynski SR. Isolation and purification of habituation inducing peptides from brains of trained rats. Fed Proc. 1973;32:367.
12. Burzynski SR, Ungar AL, Lubanski E. Biologically active peptides in human urine, II: effect on smooth muscle and frog heart. Physiol Chem Phys. 1974;6:457-473.
13. Burzynski SR, Ungar AL, Lubanski E. Effect of urinary peptides on smooth muscle and heart. Fed Proc. 1974;33:547.
14. Leeson P. Drug News and Perspectives. Presented at the Eighth International Symposium on Future Trends in Chemotherapy; May 1988; Pisa, Italy.
15. Xu W, Yu R, Gao CH, Yuan Y, Wang H. The Preliminary Antitumor Assay of Antineoplaston A-10 Against the S-180 and the Effects on cAMP Levels in Tumor and Liver Tissues of Mice. Jinan, People’s Republic of China: Shandong Medical University, Department of Pharmacy;1988. Bulletin.
16. Lehner AF, Burzynski SR, Hendry LB. 3-Phenylacetylamino 2,6-piperidinedione, a naturally occurring peptide analog with apparent antineoplastic activity may bind to DNA. Drugs Exp Clin Res. 1986;12(suppl 1):57-72.
17. Hendry LB, Muldoon TG, Burzynski SR, Copland JA, Lehner AF. Stereochemical modeling studies of the interaction of A-10 with DNA. Drugs Exp Clin Res. 1987;13(suppl 1):77-81.
18. Muldoon TG, Copland JA, Lehner AF, Hendry LB. Inhibition of spontaneous mouse mammary tumor development by A-10. Drugs Exp Clin Res. 1987;13(suppl 1):83-88.
19. Eriguchi N, Hara H, Yoshida H, et al. Chemopreventive effect of A-10 on urethane-induced pulmonary neoplasms in mice. Jpn Soc Cancer Ther. 1988;23:1560-1565.
20. Tsuda H. Inhibitory effect of A-10 on breast cancer transplanted to athymic mice and human hepatocellular carcinoma cell lines. Kurume Med J. 1991;37:97-104.
21. LeTrombetta. An Open Letter to Patients and Friends of Burzynski Research Institute. Houston, Tex: Burzynski Research Institute; 1990.
22. LeTrombetta. An Open Letter to Dr Sam Broder, Director of NCI. Townsend Letter for Doctors. July 1990:447-450.
23. Testimony of Stanislaw R. Burzinski Before the US District Court So District of Houston, Tex. Deposition for Jos Vercellino vs Bankers Life Co, civil #H-83-416; 1984.
24. Guideline on Sterile Drug Products Produced by Asceptic Processing. Washington, DC: Center for Drugs and Biologics and Regulatory Affairs, US Food and Drug Administration; January 1985.
25. Health Industry Manufacturing Association. Microbiological Evaluation of Filters for Sterilizing Liquids. Washington, DC: Health Industry Manufacturing Association; 1981. Document 3, vol 4.
26. Westphal O. Bacterial endotoxins. Int Arch Allergy Appl Immunol. 1975;49:1-43.
27. Ashraf AQ, Liau MC, Mohabbat MO, Burzynski SR. Preclinical studies on antineoplaston A-10 injections. Drugs Exp Clin Res. 1986;12(suppl 1): 37-45.
28. James MO, Smith RL, Williams RT, Reidenberg M. Phenylacetylglutamine in the urine of man. Proc R Soc Lond Biol. 1972;182:25-35.
29. Moldave K, Meister A. Synthesis of phenylacetylglutamine by human tissues. J Biol Chem. 1957;229:463-467.
30. Sherwin CP, Kennard KS. The toxicity of phenylacetic acid. J Biol Chem. 1919;40:259-264.
31. Wen GY, Wisniewski HM, Shek JW, et al. Neuropathology of phenylacetate poisoning in rats: an experimental model in phenylketonuria. Ann Neurol. 1980;7:557-566.
32. Loo YH, Fulton T, Miller KA, et al. Vulnerability of the immature brain to phenylacetate intoxication: postnatal development of detoxification mechanisms. J Neurochem. 1979;32:1699-1705.
33. Burzynski SR. Phase I clinical studies of antineoplaston AS 2.5 injections. In: Recent Advances in Chemotherapy: Proceedings of the 14th International Congress of Chemotherapy. Kyoto, Japan; 1985:586-587.
34. Burzynski SR, Mohabbat MO, Lee SS. Preclinical studies on antineoplastons AS 2.1 and AS 2.5. Drugs Exp Clin Res. 1986;12(suppl 1):11-16.
35. Lichenstein N, Grossowicz N, Schlesinger M. Effect of phenylacetylglutamine on murine tumor cells in culture. Isr J Med Sci. 1977;13:316-320.
36. Burzynski SR. Bound amino acids in serum of patients with chronic renal insufficiency. Clin Chim Acta. 1969;25:231-237.
37. Biochemicals and Organic Compounds. St Louis, Mo: Sigma Chemical Co; 1991:779. Publication P 4515.
38. Merck Index. 11th ed. Rahway, NJ: Merck Co; 1989:703, 1458.
39. Christie GA. Thalidomide and congenital abnormalities. Lancet. 1962;2:249.
40. Di Paolo JA. Congenital malformations in strain A mice: its experimental production by thalidomide. JAMA. 1963;183:139-141.